Oxford begins first human trial of Bundibugyo Ebola vaccine
The early-stage trial, known as BD-Ebov, will evaluate the safety and immune response of the ChAdOx1 BDBV vaccine in 50 healthy adults aged 18 to 55 in Oxford, the university said on Monday.
If the early-stage trial is successful, CEPI said it would work with Oxford and Serum Institute to support late-stage studies needed to seek emergency-use authorisation or full regulatory approval.
The vaccine was developed by scientists at Oxford's Vaccine Group and Pandemic Sciences Institute using the same viral vector platform as the Oxford/AstraZeneca COVID-19 shot.
This is a summary of the original articles listed below. Always read the source articles for the full context. GhanaSummary does not create or modify the news — we summarise and link to original publishers.
